Monthly Archives: April 2016

Chelsea Oil & Gas Ltd. Announces Filing of 2015 Financial Statements and Management’s Discussion and Analysis

CALGARY, AB / ACCESSWIRE / April 29, 2016 / Chelsea Oil & Gas Ltd. (OTC Pink: COGLF) (“Chelsea”) announces that it has filed its audited consolidated financial statements and accompanying notes for the years ended December 31, 2015, 2014 and 2013, and its related management’s discussion and analysis with applicable Canadian securities regulatory authorities. Copies of these documents may be obtained through the Internet on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com.

For further information contact:

Chelsea Oil & Gas Ltd.

+1 (403) 457 1959
info@chelseaoilandgas.com
www.chelseaoilandgas.com

SOURCE: Chelsea Oil & Gas Ltd.

ReleaseID: 439413

ChroMedX Reports on HemoPalm Development

TORONTO, ON / ACCESSWIRE / April 29, 2016 / ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the “Company“), a developer of in vitro diagnostics and Point-of-care Testing technologies is pleased to report on the Company’s HemoPalm development programme.

During the first four months of 2016, ChroMedX focused on refining the HemoPalm cartridge design through machining, and developing essential components of the HemoPalm analyzer.

“We have made significant progress so far in 2016 and are very pleased that there have been several important developments which will expand the utility and market of the HemoPalm. We have successfully engaged new technical resources and have concentrated efforts on our cartridge and biosensor technologies. The Company is now focused on optimizing the cartridge development in order to shift to the process of molding, and completion of the breadboard analyzer for testing the cartridges,” said Dr. Wayne Maddever, President & CEO.

HemoPalm Development

The HemoPalm project has made progress on several key fronts. The HemoPalm system consists of a disposable single use cartridge and a handheld analyzer. The system utilizes both spectroscopic measurements for CO-oximetry and bilirubin, and biosensor measurements for blood gases and electrolytes.

Proof-of-concept for CO-oximetry and bilirubin was completed. CO-oximetry is the gold standard for hemoglobin and oxygen saturation measurements and the inclusion of this technology makes the HemoPalm the only hand held analyzer in the world to combine CO-oximetry, blood gases and electrolytes. In addition, the successful demonstration of the measurement of bilirubin, an indicator of liver function and essential for the detection of neonatal jaundice, will expand the market for the HemoPalm.

The other critical development area is that of the electrochemical sensors used in the cartridge. ChroMedX recently announced the addition of Conductive Technologies Inc. (CTI) of York, PA. to this effort that is led by Polygenesis. CTI, which produced the current gold sensor array on a polymer substrate brings over 60 years of sensor and electronics expertise to the project and is leading the development of automated deposition of the critical ion selective membranes to the sensor array. Polygenesis has a long history in the field and the principal was part of the development team that created the Abbott i-Stat analyzer.

The Company previously reported on the cartridge development work being undertaken with Shenzhen Hochuen Technologies Co. Ltd. of Shenzhen China. Led by Dr. James Samsoondar, ChroMedX CSO, the cartridge has undergone several iterations of design refinement and recently demonstrated blood flow into the optical chamber by capillary action, for subsequent spectroscopic analysis. Design of the microfluidics is a critical aspect of the cartridge design and is patent protected. Another patent protected aspect of the cartridge design will allow for sample collection from a simple finger prick, or heel prick in the case of neonates, directly into the cartridge without the need for collection with a capillary tube and subsequent transfer. This aspect of the HemoPalm cartridge is not available in any hand-held or lab blood gas analyzer.

After successfully testing cartridges on the breadboard analyzer as mentioned before, the next step would be to package the analyzer components into a hand-held analyzer, and proceed towards clinical testing of the HemoPalm system for FDA submission.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.:

Website: www.chromedx.com
Facebook: facebook.com/chromedxcorp
Twitter: www.twitter.com/Chromedxcorp

Investor Enquiries:

Shawn Overton
d. 647-528-9344
o. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
soverton@ChroMedX.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com

SOURCE: ChroMedX Corp.

ReleaseID: 439410

Endpoint Security Market to See a Growth of 8.4% CAGR to 2020, Acccording to New Research

The endpoint security market to grow USD 17.38 billion by 2020 at a projected CAGR of 8.4% from 2016 to 2020 driven by the need to mitigate IT security risks and increase in the frequency of internal threats with endpoint device control to gain maximum traction during the forecast period.

Pune , India – April 29, 2016 /MarketersMedia/ —

The worldwide endpoint security market size is estimated to grow from USD 11.62 billion in 2015 to USD 17.38 billion by 2020, at an estimated Compound Annual Growth Rate (CAGR) of 8.4% from 2015 to 2020. The need to mitigate IT security risks will drive the endpoint security market

Complete report on global endpoint security market spread across 162 pages, profiling 10 companies and supported with 71 tables and 55 figures is now available at http://www.rnrmarketresearch.com/endpoint-security-market-security-suites-epp-anti-virusmalware-firewall-ids-ips-patch-configuration-management-byod-security-mobile-security-mdm-mam-endpoint-encryption-global-advanc-market-report.html .

The global endpoint security market is driven by factors, such as the need to mitigate IT security risks, growing Bring Your Own Device (BYOD) trends among organization, and increase in the frequency of internal threats.

Endpoint device control is to gain maximum traction during the forecast period. The anti-virus solutions are estimated to contribute the largest market share during the forecast period. Furthermore, due to rise in demand for mobile and tablet security solutions, endpoint device control is expected to gain traction and would grow at the highest CAGR in the next five years. The endpoint security market is also projected to witness growth in the BFSI, healthcare, and IT and Telecom verticals, with government and defense vertical contributing the largest market share during the forecast period.

In the process of determining and verifying the market size for several segments and sub-segments gathered through secondary research, extensive primary interviews were conducted with key people. In Tier 1 (55%), Tier 2 (20%), and Tier 3 (25%) companies. The interviews were conducted with various key people such as C-level (60%), director level (25%), and other executives (15%) operating in the endpoint security market. The primary interviews were conducted worldwide covering regions such as North America (10%), Europe (20%), APAC (40%), and RoW (30%).

Due to rise in the demand for integrated endpoint security solutions and increasing adoption of cloud-based security solutions, the endpoint security market finds huge opportunity to proliferate in the next five years.
The major players in the global endpoint security market are Symantec, Intel Security, Trend Micro, AVG Technologies, Sophos, Kaspersky Labs, F-Secure, ESET, Panda Security and Bitdefender. Ask for a discount before order a copy of Endpoint Security Market by Solution (Anti-Virus, Antispyware/Antimalware, Firewall, Endpoint Device Control, Intrusion Prevention, and Endpoint Application Control), Service, Deployment Type, Organization Size, Vertical, and Region – Global Forecast to 2020 research report at http://www.rnrmarketresearch.com/contacts/discount?rname=156896 .

This report segments the endpoint security market comprehensively and provides the closest approximations of the revenue numbers for the overall endpoint security market and the sub segments across different verticals and regions. The report also helps stakeholders to understand the pulse of the market and provides them information on key market drivers, restraints, challenges, and opportunities.

On a related note, another research titled Security Analytics Market Global Forecast to 2020, says the market size is estimated to grow from USD 2.1 billion in 2015 to USD 7.1 billion by 2020, at an estimated CAGR of 27.6% from 2015 to 2020. Rise in the sophistication level of security breaches to drive the security analytics market. Endpoint security analytics is to gain maximum traction during the forecast period. Companies like Cisco Systems, IBM, HP, EMC RSA, Juniper Networks, FireEye, Arbor Networks, LogRhythm, Inc., Click Security and Blue Coat Systems profiled in this 166 pages research available at http://www.rnrmarketresearch.com/security-analytics-market-by-types-network-security-application-security-data-and-information-security-physical-security-mobile-security-worldwide-market-forecasts-and-analysis-2013-2018-market-report.html .

About Us:

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets.

For more information about us, please visit http://www.rnrmarketresearch.com

Contact Info:
Name: Ritesh Tiwari
Organization: RNR Market Research
Address: UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar
Phone: +1-888-391-5441

Source: http://marketersmedia.com/endpoint-security-market-to-see-a-growth-of-8-4-cagr-to-2020-acccording-to-new-research/112713

Release ID: 112713

International Consolidated Companies (OTC: INCC) Shareholder Update on St. James Remedies (SJR)

NAPLES, FL / ACCESSWIRE / April 29, 2016 / International Consolidated Companies (OTC: INCC) shareholder update on St. James Remedies (SJR).

SJR has executed a letter of intent to joint venture with Reakiro Labs LTD, a UK based producer of Natural, Organic, Bio-Dynamic, phyto-cannabinoid rich, full Entourage effect CBD oil extract. http://www.reakirolabs.com Reakiro, [pronounced Ree A Keer O] which means “Recovery” in Esperanto, has partnered with many “Artisanal Family Farmers” throughout Europe and is sitting on what we believe to be the largest supply (2,000 plus Kilos) of Super High
Quality Hemp Oil Extract in the world.

“We are excited to be working together with REAKIRO to develop new products and delivery systems. By using the best and most consistent quality CBD rich hemp oil extract available, SJR / Reakiro will build a business centered around helping people,” said Antonio Uccello.

“Having had previous experiences with large industrial farms and their inability to produce consistent, clean and vibrant product, Reakiro determined that the only way to get the outstanding results for their customers was to provide them with the best of the best. As such, artisanal family farms are the only way to achieve our mission. We are excited to work with SJR as we are aligned with the same values!” said David Neisingh President, Reakiro Labs LTD.

SJR engaged a South Florida co-packer, who has developed over 800 products, to produce several of its new CBD rich, Hemp Oil Extract products. “We continue our requirement of excellence. We expect to be releasing updates and timelines on our new products starting next month,” said Adam Ardenfriend, President SJR.

SJR is taking an option with Brooks Kelly research, LLC, based in Colorado, on IP (http://www.google.com/patents/US8642645) covering a process to improve bioavailability by allowing absorption through the upper digestive tract, mitigating the first pass metabolism issue that degrades over 90% of active cannabinol thus, optimizing absorption through the upper digestive track. The result of this IP is that the active cannabinoids can last up to 12 hours in vivo and a reduced dosage is possible to achieve the same pain management effects. All of this is accomplished by utilizing food grade ingredients that are generally recognized as safe (GRAS) by the FDA. This IP was developed by Dr. Brooks J. Kelly and includes numerous trade secret product formulations and issued patent and patent application with allowed claims.

“The human body cannot assimilate oils very well. We believe this IP will enable SJR to produce the best, most efficient delivery systems increasing the ability making it, in our opinion, the faster, better solution, while saving money and establishing a cutting edge,” Stated Adam Ardenfriend.

/s/
Adam Ardenfriend, President

/s/
Antonio Uccello, Chairman of the Board

International Consolidated Companies (INCC) was founded in 2002. INCC and its subsidiaries are in the business of people – helping people, through the development of quality hemp products and services, which bring new energy to the world and will ultimately create prosperity for investors. INCC is focused on acquiring and growing businesses that offer innovation, quality, and cost-efficient technologies.

Forward-looking
disclaimer

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material may contain statements about expected future events and/or financial results that are forward-looking in nature and subject to risk and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements to be materially different from the statements made herein.

CONTACT:

Adam Ardenfriend, President
305-707-7780
info@stjamesremedies.com

SOURCE: International Consolidated Companies, Inc.

ReleaseID: 439404

Direct Dental Sales Explode: Smile Perfected Announces Direct Sales Rival Distributor Model

The Dental distributor model is at risk of dying a slow death announced dental product company Smile Perfected, well known for their popular in-office whitening systems.

Fort Lauderdale, United States – April 29, 2016 /MarketersMedia/ —

In a question and answer statement issued by the teeth whitening company responsible for the Prophy Plus™ and the 20-Minute Whitening System™, Smile Perfected™ revealed a surge in direct to doctor sales for their products and shared their concerns for the dental distributor model dominant for decades in dentistry – pulling no punches.

“The major dental distributors aren’t as necessary anymore, and don’t provide the value to the dental practices they supply or the product manufacturers as they used to. The internet has put them in danger of becoming irrelevant – if they don’t adapt,” stated Dr. Balanoff, Smile Perfected CEO & Founder, Dr. William Balonoff, DDS, MS, FICD.

Dr. Balanoff attributes their success with being able to communicate directly (doctor to doctor) with practice owners without a gatekeeper. The Smile Perfected 20-Minute Whitening System was designed to fit perfectly into an office’s existing routine. Patients can get a pain free, sensitivity free whitening treatment in just 20 minutes, and it’s easy for the hygiene team to perform. It was designed by a dentist with a dentist’s needs in mind and the system was made available online here: http://www.smileperfected.com/direct-sales/.

Dr. Balanoff made it clear that the large distributors (the Big 3 including: Henry Schein, Patterson Dental, and Benco) have been great partners throughout his career as doctor, practice owner and dental product manufacturer.

“We have a product that provides incredible value to practice owners and group dentals, which can dramatically raise hygiene revenues, increase patient satisfaction all without tying up doctor time,” stated Dr. Balanoff.

The company found the catalog / sales rep system predominant in many dental offices across the U.S. insufficient at getting this message out to dentists who could benefit according to the statement. The company revealed they began to see the sales of their popular whitening system explode when they began to reach dentists directly, sidestepping the traditional gatekeeper. Doctors would get it immediately, and understand the value of the Smile Perfected 20-Minute Whitening System™ for their dental office – when they could reach them.

Companies like Henry Schein, the largest distributor of dental products which supplies 100,000 dental offices, Benco and Patterson Dental thrived providing a catalog of dentistry products, and provide a real convenience to doctors who just want to practice dentistry according to Dr. Balanoff.

Sales surged past their initial benchmark of 150 partnered offices, and new office acquisitions from large dental suppliers only account for a small fraction of the new offices added, according to the Smile Perfected.

“Working direct with dental offices interested in our product allows us to provide insane value, and our product support is unsurpassed,” added Dr. Balanoff.

Great companies offering dental supplies like Henry Schein, Patterson & Benco aren’t going away and will likely be with dentists for years to come – but they will need to adapt to an internet age to stay relevant, according to at least one dental product manufacturer.

About Smile Perfected:
Smile Perfected was established in 2014 by Dr. William Balanoff. Dental products include the Smile Perfected 20 Minute Whitening System™, designed to fit seamlessly into an offices current patient process after a prophy. Imagine a patient getting a quick, noticeably whiter smile with a non-invasive dental service… no drilling, no shots… just whiter teeth in 20 minutes. To learn more visit: https://www.smileperfected.com

For more information about us, please visit https://www.smileperfected.com

Contact Info:
Name: Dr. William Balonoff, DDS, MS, FICD
Organization: Smile Perfected™
Address: 3000 Ravenswood Road, Suite #1A, Fort Lauderdale, Florida 33312
Phone: 877-624-6674

Source: http://marketersmedia.com/direct-dental-sales-explode-smile-perfected-announces-direct-sales-rival-distributor-model/112815

Release ID: 112815

David Huff Of David & The Giants Has Released His New Cd “Born For This”

David Huff, Artist and Guitarist from the well-known band “David & The Giants”, has announced the release of his new album entitled “Born For This.”

Good Hope, Georgia, United States – April 29, 2016 /MarketersMedia/ —

This is the sixth album that David Huff has recorded as a solo artist since David & The Giant took a “time out” 1997. David sings about his life story of what he was born for in the “Born For This” CD Album. “Born For This” contains many new inspiring songs and the best music he has recorded to date. Anyone new to his music or a raving fan, “Born For This” will instantly impact your heart and soul.

David in his early years formed his first rock band and followed the road of rock with an amazing band called David & The Giants (with one of the band members being Keith Thibodeaux from the I Love Lucy Show) and David’s twin brothers Clayborn and Rayborn Huff. David & The Giants started as a rock band which later became a christian rock band with performances over a span of almost 40 years and an astounding 17 albums. They shared the stage with famous artists like Cheech and Chong, Chuck Berry, Black Oak Arkansas, Styx and others.

Some of David & The Giant’s recordings became a music sensation in England in the 1970’s as Northern soul, in which songs were that had a combination of Top 40 music. The year 1969 was huge for the band with the release of singles called “Superlove” and “Ten Miles High” which was popular both in the United States and England.

As a result of a spiritual revelation, David Huff disbanded his old music labels and opened up his own studio called Huff Recording Studio to sing his own songs and spread the message of Jesus to others. The songs follow the journey of his life, the moment of enlightenment and spiritual awakening, and the true meaning of his life so that he could share what he born for. Over years, he had several popular artists like Tommy Sims, KC & Jo Jo, Chris Tomlin, The William Brothers, David Dykes and others record their songs in his studio as well.

“Born For This”, like the previous solo albums of David Huff, are released on the record label Giant Records. The songs he plays are Christian Rock and his lyrics praise God and His merciful nature. The lyrics speak of hope, optimism and eternal love, and rediscovering our true quests in life.

According to David Huff, “Every person has a purpose on this earth. Our job is to find it and then fulfill it.”

David Huff says, “His songs instantly connect with his listeners and teach them the value of their souls.”

About David Huff:
David Huff was born to be a musician. At the age of eleven he started playing the guitar and performing at the local radio station in Mississippi while growing up. At a young age, he formed his own band and played secular music not knowing he would eventually be singing for the Lord. As a legendary artist himself with the band David & The Giants, they were signed with MGM Records, CBS Records, United Artist Records and Capitol Records. David now performs solo and on special occasions some dates with David & The Giants, never giving up his quest to teach people about the Lord and His beautiful plan. Two songs like “My Song of Praise” and “You Saved My Life” became hits that topped the Radio Charts. A song called “The Best is Yet to Come” was a very successful upbeat song among many music lovers.

Purchase CD here http://davidhuff.com/born-for-this/downloads/dh-born-mp3/

For more information about us, please visit http://www.davidhuff.com

Contact Info:
Name: Huff Recording Studios
Email: info@huffrecording.com
Organization: Huff Recording Studios
Address: P.O. Box 248 Good Hope, Georgia 30641
Phone: 770-266-5266

Source: http://marketersmedia.com/david-huff-of-david-the-giants-has-released-his-new-cd-born-for-this/112864

Release ID: 112864

One Page Website Online Marketing Sales Funnel Training Service Launched

A brand awareness tips, tricks and strategy website has launched that covers a wide variety of techniques people can use to increase traffic online. Profit With David features video training, and a list of reports and guides to help people drive more website traffic.

Dallas TX, USA – April 29, 2016 /PressCable/ —

A new site has launched that focuses on helping people to create online marketing campaigns, updated daily with news, reports, and key findings to allow people to drive traffic to their business. Profit With David features video training, lead generation, and network opportunities and has a subscriber newsletter that provides additional tips for entrepreneurs and business owners.

More information can be found on the Profit With David website at: http://profitwithdavid.com.

The Profit With David site explains how it can sometimes be difficult to find ways to market an online business, and seeks to help people of all knowledge levels to create, maintain and develop marketing strategies to drive traffic to their site. A recent report covers a number of beginner tips, like how to get people to sign up to subscriber lists, which can lead to targeted marketing campaigns with high success rates. It also shows users how to find out where traffic is coming from, so they can better understand their audience.

Other guides focus on the importance of simple website design, with non-cluttered layouts and clear navigation. They explains that most people don’t like navigating through a site that is overly busy or has confusing elements to it, because they want to be able to find the products they like within a few clicks of arriving on the site.

The Profit With David site also covers new products and software available on the web that can help to increase awareness of a company by generating leads. Products like Online Sales Pro can help users to find leads, manage leads, and email people with targeted automated campaigns that are tailored to their interests.

A number of different brand awareness strategies are covered, which vary from making use of eBay and Instagram to spread the word of someone’s business, to marketing tips and tricks that can increase search engine results rankings and garner more attention, helping to increase conversion when people click through onto the business site. Anyone with questions for David can contact him using a contact form provided on the site.

For more information about us, please visit http://profitwithdavid.com

Contact Info:
Name: David Kilburn
Organization: Profit With David
Phone: 8066813345

Release ID: 112960

Four Top Stocks: Investors Are Considering These on Friday April 29th

MIAMI, FL / ACCESSWIRE / April 29, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. EHTH, CYBE, COOL, and PRGN have been added to our watch list today. Continue reading to find out why. – To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.

eHealth, Inc. (NASDAQ: EHTH) announced first quarter results this week. Among the highlights, the company reported revenue for first quarter of $73.8 million, an increase of 20% compared to the first quarter of 2015. Adjusted EBITDA for first quarter of $26.8 million compared to adjusted EBITDA of $5.8 million for the first quarter of 2015 and cash flow from operations for first quarter was an inflow of $4.7 million compared to an outflow of $11.2 million in the first quarter of 2015. The company operates eHealth.com, the nation’s first and largest private health insurance exchange where individuals, families and small businesses can compare health insurance products from leading insurers side by side and purchase and enroll in coverage online. Since closing at $8.89, shares have increased to highs of $11.49 on Friday marking a total move up of nearly 30%

Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here.

CyberOptics Corp. (NASDAQ: CYBE) is a leading global developer and manufacturer of high precision sensing technology solutions. On Thursday the company reported operating results for the first quarter of 2016 ended March 31. These included first quarter sales totaled $19.1 million, double the $9.5 million reported in the first quarter of 2015. Additionally, CyberOptics reported earnings of $2.3 million or $0.33 per diluted share in the first quarter of 2016, compared to the loss of $781,000 or $0.12 per share in the year-earlier period. For the period beginning April 12, the company’s stock price has increased from $9.51 to highs of $17.40 on Friday. This represents a move up of 83%.

Subscribe Now And Reserve A Spot To Receive Our First Alert Of April. Get Your Free Membership Now.

Majesco Entertainment Company (NASDAQ: COOL) develops, publishes, markets, and distributes video game products for mass market and casual-game players worldwide. The company publishes video games for various interactive entertainment hardware platforms through its Midnight City label, including Nintendo’s DS, DSi, 3DS, Wii and WiiU, Sony’s PlayStation 3, Microsoft’s Xbox 360 and Xbox One, and the personal computers. It also publishes games for various digital platforms consisting of Xbox Live Arcade, PlayStation Network, and Steam; and mobile platforms, such as the iOS and Android phones. Majesco Entertainment Company was founded in 1998 and is headquartered in South Plainfield, New Jersey. Over recent weeks, the stock has traded in the 80 cent range and over the last 45 days, COOL shares have seen price as high as $0.99.

Enjoy picks like this? Get These Alerts and More on NASDAQ Companies before They Rally, Text the word “NASDAQ” to 77948.

Paragon Shipping Inc. (NASDAQ: PRGN) is an international shipping company incorporated under the laws of the Republic of the Marshall Islands with executive offices in Athens, Greece, specializing in the transportation of drybulk cargoes. Paragon Shipping’s current fleet consists of six drybulk vessels with a total carrying capacity of 297,879 dwt. In addition, Paragon Shipping’s current newbuilding contracts consist of three Kamsarmax drybulk carriers. Since April 27, shares of PRGN have increased from $0.26 to highs on Friday of $3.94. This was a move up of more than 1,400% in 3 days. Earlier this week the company announced the expiration of its previously announced offer to exchange all properly delivered and accepted 8.375% senior notes due 2021.

Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here.

About TopNasdaqStocks.com

Looking for stock market and business news headlines? How about up to the minute information on mutual funds and ETFs? Don’t forget about the top stock picks of 2016. TopNasdaqStocks.com has it all. Make sure to subscribe to our free newsletter and to receive free text message alerts on your phone, text “NASDAQ” to 77948.

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Pursuant to an agreement between us and a non affiliate 3rd party we were hired for a period beginning on 3/20/16 and ending on 6/19/16 to publicly disseminate information about (cool) including on the website and other media including facebook and twitter. We are being paid $100,000 (cash) for or were paid “zero” shares of unrestricted or restricted common shares. We own zero shares of (cool), which we purchased in the open market. We plan to sell the “zero” shares of (cool) that we hold during the time the website and/or facebook and twitter information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (cool) in the open market at any time, including before, during or after the website and information, provide public dissemination of favorable information. Top Nasdaq Stocks has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding PRGN, CYBE, or EHTH in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. Top Nasdaq Stocks is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit http://topnasdaqstocks.com/index.php/disclaimer/ website for a more detailed discussion of risks and disclosures.

Contact:

Top Nasdaq Stocks
news@topnasdaqstocks.com

SOURCE: Top Nasdaq Stocks

ReleaseID: 439405

Xarelto Bleeding Lawsuit Filings Transferred And Consolidated By JPML Under U.S. District Judge Eldon Fallon

April 29, 2016 – – BloodThinnerHelp.com reports on the transfer and consolidation of all federally-filed Xarelto related lawsuits by the U.S. Judicial Panel on Multidistrict Litigation. The cases are able to be filed, forming MDL number 2592, due to the fact that they were filed against the same defendants (Bayer and Janssen) and that they contain strikingly similar plaintiff allegations.

The complaints were transferred to a single court in Eastern Louisiana and are now being overseen by the Honorable U.S. District Judge Eldon E. Fallon. The consolidation was issued on December 12, 2015, generating the transfer of these federal cases, and helping to “fast track” the litigation process by avoiding duplicative discovery or different rulings from multiple judges. It will also help to conserve resources for everyone involved.

In just five year’s time, Xarelto lawsuits have grown to number more than 3,400, and have been consolidated to form two major groupings. Lawsuits consolidated in the MDL number over 2,800 and are expected to continue to rise. In addition, these lawsuits are joined by more than 620 other cases which were consolidated to form a mass tort program by the Court of Common Pleas in Philadelphia, Pennsylvania. Plaintiffs involved in these lawsuits synonymously allege that use of new-generation blood-thinning drug Xarelto places users at increased risk for the development of sudden bleeding events, some of which can be life-threatening and prove fatal.

The MDL consolidation decision came in response to a request from a group of plaintiffs submitted in October 2015. The request asked that the JPML centralize the cases to help litigation run more smoothly and efficiently. Initially, plaintiffs asked that the involved cases be centralized in the Southern District of Illinois. The defendants contested this request, however, arguing that the cases should be centralized in New Jersey, where their headquarters were located. Defendant Janssen Pharmaceuticals is a division of corporate giant Johnson & Johnson.

After a hearing session which was held on December 4, 2015, the JPML noted, “In our judgement, the considerable growth in the litigation over the past few months demonstrates that informal coordination is not practical.” Additionally, they stated that they had determined the lawsuits would be overseen by the Honorable Judge Eldon Fallon, and explained, “Judge Eldon E. Fallon, who presides over three potential tag-along (Xarelto) actions, is an experienced transferee judge with the willingness and ability to manage this litigation efficiently. He is well-versed in multidistrict litigation, and we are confident he will steer this matter on a prudent course.”

As the plaintiffs involved in Xarelto lawsuits anxiously await trial dates, many anticipate that filing numbers will continue to steadily grow. At this time, Attorney Joseph Osborne is working to help other patients who have used Xarelto and who feel that the blood thinner has negatively affected their health. He wants to help ensure that all affected patients are provided with an opportunity to fully explore their legal rights, as they may be entitled to significant compensation attained through legal action. To assist those who wish to investigate their options further, Attorney Osborne is now offering complimentary legal consultations to affected parties.

To request further Xarelto lawsuit information, or to ask questions, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009685

Invokana Lawsuit: Plaintiff Alleges Side Effects Including Kidney Failure Requiring Kidney Transplant

April 29, 2016 – – TheProductLawyers.com reports on an Invokana lawsuit plaintiff’s allegation which claims that there is a link between new-generation diabetes drug Invokana, made by Janssen Pharmaceuticals, and kidney failure. The plaintiff alleges that users of Invokana can suffer kidney damage and failure due to their use of the drug. In addition to the plaintiff’s allegations the FDA has reported receiving 50 reports which relate to kidney failure and renal impairment from patients who have taken the drug.

Invokana is in a class of drugs known as SGLT2 inhibitors which are designed to help maintain control of blood sugar levels. This is done by keeping excess glucose from being reabsorbed into the kidneys. Instead, it uses the kidneys to push that excess glucose out of the body, through urination. In order to accomplish this excess work is required from the kidneys. As a possible result of this excess strain there have been many cases of kidney damage which can cause kidney failure if left untreated.

Approximately 6 months ago, the FDA announced new requirements for the warning labels of Invokana, requiring the manufacturer of the drug to adjust them to contain information related to the possible side effects being reported. The primary effects that were required to be listed were ketoacidosis and urinary tract infections, which have been reported in a high numbers of patients who have taken the drug.

The FDA has also stated that they received a total of 19 adverse event reports in which individuals sustained additional serious potentially life-threatening problems which began as urinary tract infections. These health problems then developed into kidney infections and blood infections that required hospitalization and dialysis for kidney failure. Kidney damage is not able to be repaired, so those who suffer from extreme damage and kidney failure would likely require a complete kidney transplant.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009591